Source comparison
CJC-1295 DAC Same as CJC-1295: Pharmacokinetic Comparison
Half-Life 6–8 days ~30 minutes DAC version requires weekly dosing; non-DAC requires multiple daily administrations Peak GH Response Gradual elevation over 48–72 hours, sustained for 5–7 days Sharp spike within 30–60 minutes, returns to baseline within 2 hours
This comparison does not assign a generated winner or score.
- Half-Life
- 6–8 days
- ~30 minutes
- DAC version requires weekly dosing; non-DAC requires multiple daily administrations
- Peak GH Response
- Gradual elevation over 48–72 hours, sustained for 5–7 days
- Sharp spike within 30–60 minutes, returns to baseline within 2 hours
- DAC produces blunted, prolonged effect; non-DAC mimics physiological pulsatility
- Typical Dosing Frequency
- Once or twice weekly
- 2–3 times daily
- Total peptide load per week is similar, but administration burden differs significantly
- Binding Mechanism
- Covalently binds to serum albumin via DAC modification
- No albumin binding—relies on receptor affinity only
- DAC modification prevents enzymatic degradation; non-DAC is rapidly cleaved by DPP-4
- IGF-1 Elevation Pattern
- Steady increase over 7–10 days
- Pulsatile increases correlated with dosing times
- DAC provides consistent anabolic signaling; non-DAC better for circadian rhythm studies
- Professional Assessment
- Optimal for long-duration studies requiring stable GH levels; less ideal for mimicking natural secretion
- Preferred for protocols examining GH pulsatility or combining with GHRP agonists requiring acute response